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AGE-Modified Collagens I and III Induce
Keratinocyte Terminal Differentiation through AGE
Receptor CD36: Epidermal–Dermal Interaction in
Acquired Perforating Dermatosis
Eita Fujimoto1, Takashi Kobayashi1, Norihiro Fujimoto1, Minoru Akiyama1, Shingo Tajima1 and Ryoji Nagai2
To clarify the molecular mechanism underlying the transepidermal extrusion of dermal collagen in acquired
perforating dermatosis (APD) associated with diabetes mellitus and renal failure, we studied the interaction
between advanced glycation end product (AGE)-modified extracellular matrix proteins and keratinocytes (KCs)
in a cell culture system. The expression of involucrin (INV) and keratin 10 was significantly enhanced in normal
human KCs grown on AGE-modified collagen I or III compared with cells grown on unmodified collagen I or III.
Glycated collagens I and III preferentially induced the expression of AGE receptor CD36, but not of other AGE
receptors. KCs induced to terminal differentiation demonstrated markedly elevated CD36 expression. Glycated
collagen I- and III-induced INV expression was partially blocked by the anti-CD36 antibody (Ab). These
substrates also induced epidermal matrix metalloproteinase 9 (MMP-9) expression. Lesional skin from APD
patients reacted moderately or strongly with the anti-CD36 Ab as well as the anti-MMP-9 Ab in the epidermal
cells surrounding the collagenous materials being eliminated. These results suggest that exposing KCs to
AGE-modified interstitial collagen (types I and III) by scratching induces terminal differentiation of KCs via the
AGE receptor (CD36), leading to the upward movement of KCs together with glycated collagen.
Journal of Investigative Dermatology (2010) 130, 405–414; doi:10.1038/jid.2009.269; published online 29 October 2009
INTRODUCTION
Transepidermal elimination (TEE) has been recognized as a
fundamental cutaneous elimination mechanism that may
target inflammatory cells, erythrocytes, keratotic materials,
connective-tissue components, foreign materials, and infec-
tious organisms. Although TEE occurs as a secondary
phenomenon in a variety of conditions, it is a primary
characteristic feature of four perforating skin disorders:
reactive perforating collagenosis and elastosis perforans
serpiginosa, characterized by TEE of collagen and elastic
fibers, respectively, and perforating folliculitis and Kyrle’s
disease, both characterized by TEE of keratotic materials.
Because TEE of collagen fibers is clinically identical in skin
lesions of reactive perforating collagenosis patients with
diabetes mellitus and renal insufficiency, the term ‘‘acquired
perforating dermatosis’’ (APD) has been proposed for this
new entity (Poliak et al., 1982; Patterson, 1989). The
mechanism by which dermal collagen is transepithelially
eliminated in APD remains unknown. Linear development of
the eruption along scratch marks (the Koebner phenomenon)
is observed in almost all APD patients, suggesting that even a
minor trauma caused by scratching plays a large part in the
development of APD lesions by producing papillary dermal
necrosis because of poor blood supply due to diabetic
vasculopathy (Poliak et al., 1982; Patterson, 1989).
In diabetes mellitus patients, long-term hyperglycemia
induces a modification of protein structures by a none-
nzymatic Maillard reaction between amino groups and
carbohydrate-derived aldehyde groups to produce Schiff
bases and Amadori products in vivo, leading to the
production of advanced glycation end products (AGEs). Type
I and III collagens are major dermal constituents comprising
80% of the dermal extracellular matrix (ECM). Because
collagens are long-lived proteins, they are especially suscep-
tible to glycation-induced damage. Diabetic patients have an
elevated AGE level in skin collagen, and long-term glycation
of collagen is significantly associated with severe complica-
tions in these patients (Dyer et al., 1993; Monnier et al.,
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1999; Genuth et al., 2005). AGE receptors, members of the
immunoglobulin superfamily of cell surface receptors,
including the receptor for AGE (RAGE) (Neeper et al.,
1992), galectin-3 (Gal-3) (Vlassara et al., 1995), CD36
(Ohgami et al., 2001a), macrophage class A scavenger
receptor (SR-A) (Nagai et al., 2000), and class B scavenger
receptor type I (SR-BI) (Ohgami et al., 2001b) interact with
several AGE ligands. RAGE is expressed in a wide variety of
tissues and cells, including skin fibroblasts, keratinocytes
(KCs), monocytes, macrophages, and T lymphocytes (Brett
et al., 1993; Wautier and Guillausseau, 2001; Lohwasser
et al., 2006). Human KCs also express SR-BI (Tsuruoka et al.,
2002), CD36 (Simon et al., 1996), and Gal-3 (Saegusa et al.,
2008). CD36 is a multifunctional receptor that binds oxidi-
zed low-density lipoprotein, collagen, thrombospondin-1,
and fatty acids. The broad ligand specificity of CD36 suggests
multiple roles for this protein (Ge and Elqhetany, 2005).
The most important function of epidermal KCs is the
production of keratin or keratin-related proteins, for example,
involucrin (INV) and filaggrin, during differentiation (kerati-
nization) by migrating upward from the basal layer to the
spinous, granular, and horny layers. KCs are programmed to
express differentiation-specific proteins in the early, late, and
terminal stages of differentiation and thus produce keratin 10
(K10) during early differentiation and INV during terminal
differentiation (Eckert, 1989; Dlugosz, 1996).
Terminal differentiation of KCs is regulated by their
interaction with the ECM (Watt et al., 1993). In normal
human skin, basal epidermal cells rest on the basement
membrane and associate with ECM components of the
basement membrane, including laminin, fibronectin, and
collagen IV. In wound healing or epidermal repair, migrating
epidermal cells associate directly with dermal ECM compo-
nents, including collagens I, III, and V, and migrate efficiently
on the dermal ECM.
In this study, we investigated the interaction of cultured
human KCs with AGE-modified collagen in order to under-
stand the molecular mechanism by which TEE of AGE-
modified collagen occurs in APD.
RESULTS
Expression of INV and K10 in cultured KCs grown on
AGE-modified ECM
Preliminary experiments confirmed that CML (N(e)-(carbox-
ymethyl)lysine) was significantly generated in glycated dishes
coated with collagens I, III, and IV, fibronectin, and laminin,
whereas it was under the detectable level in unglycated
plates.
The expression of INV and K10, marker proteins of
terminal and early differentiation, by cultured KCs grown
for 12, 24, and 48 hours on AGE-modified collagen I, III, IV,
and V; fibronectin; and laminin was determined by real-time
PCR. When the cells were grown on AGE-modified collagen I
or III, the INV expression increased 4- and 2.5-fold,
respectively, compared with cells grown on unmodified
collagen I or III. In contrast, cells grown on AGE-modified
collagen IV or V, fibronectin, or laminin showed no marked
stimulation of INV and K10 expression (Figure 1, upper and
lower panels), although, to a lesser extent, collagen IV and
laminin substrates increased INV expression after 48 hours
of treatment. Control experiments using laminin and
fibronectin substrates modified with AGE before coa-
ting failed to induce INV and CD36 expression (data not
shown).
Expression of AGE receptors in cultured KCs grown on
AGE-modified collagen I or III substrate
We investigated the main receptors (CD36, Gal-3, RAGE,
SR-BI, and SR-A) involved in the interaction between AGE-
modified collagen I or III and KCs. CD36 expression in KCs
was preferentially increased sixfold when cultured in the
AGE-modified collagen I substrate during a 48-hour incuba-
tion and threefold in the AGE-modified collagen III substrate
during a 24-hour incubation, whereas a relatively small
change was observed in the AGE-modified fibronectin
substrate. There was no significant increase in the expression
of other AGE receptors (Gal-3, RAGE, and SR-BI) by AGE-
modified collagen (I and III) or fibronectin substrates
(Figure 2). Basal expression of SR-A in cultured KCs was
not detectable (data not shown).
Inhibition of AGE-modified type I collagen-induced INV
expression by neutralizing AGE receptors
To further investigate the AGE receptor type involved in the
interaction between AGE-modified collagen I and KCs, we
used blocking antibodies (Abs) for CD36 and RAGE. KCs
were grown for 48 hours on AGE-modified collagen I in the
presence or absence of blocking Abs. After a 48-hour
incubation, INV expression in KCs cultured in AGE-modified
collagen I substrate was partially (B27.7%) suppressed by
the addition of the anti-CD36 Ab at 10 and 25 mgml1
concentrations. The Ab to RAGE showed no effect on INV
expression (Figure 3a).
This result was confirmed by immunofluorescence assays
in which the increase in cell number reacting with the anti-
INV Ab was partially blocked by the anti-CD36 Ab
(25 mgml1), but not by the anti-RAGE Ab (25 mgml1)
(Figure 3b).
Expression of AGE receptors during terminal differentiation
of cultured KCs
Keratinocytes were induced to terminally differentiate by
suspending them in 1.5% methylcellulose for 0, 24, and
48 hours (Adams and Watt, 1989). The relative mRNA level
of INV was predictably increased (B25-fold). The relative
mRNA levels of RAGE and Gal-3 increased slightly (B1.5-
and B3-fold, respectively), but the CD36 mRNA level was
markedly increased (B35-fold). In contrast, the SR-BI mRNA
level decreased during terminal differentiation, which is in
agreement with a previous report (Tsuruoka et al., 2002)
(Figure 4a). Double immunofluorescence experiments con-
firmed that a 48-hour KC suspension culture increased
the number of INV- and CD36-positive cells dramatically
(Figure 4b), indicating that CD36 expression in cultured KCs
is closely related to INV expression.
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Expression of MMP-2 and MMP-9 in cultured KCs grown
on AGE-modified ECM
We determined the relative matrix metalloproteinase 2
(MMP-2) and MMP-9 mRNA levels in cultured KCs grown
on unmodified and AGE-modified collagens (I, III, and IV)
and on fibronectin. The MMP-2 mRNA level was slightly
increased with collagen I and III substrates, but no significant
changes were observed with collagen IV or fibronectin
substrates. The MMP-9 mRNA level was induced by collagen
I and III substrates (B3.8- and B2.7-fold, respectively), but
was slightly reduced by the collagen IV and fibronectin
substrates (Figure 5a). When the cells were grown on
unmodified or AGE-modified collagen I substrate for 12,
24, and 48 hours, the content of MMP-9 in the media cultured
for 24 and 48 hours measured by a sandwich ELISA was
significantly elevated (Figure 5b, left) compared with the
MMP-2 content (Figure 5b, middle). Gelatinolytic MMP-9
activity in the media cultured for 48 hours was apparently
elevated compared with MMP-2 activity at 12 and 24 hours
(Figure 5b, right).
Immunohistochemical detection of AGE receptors
and MMP-9 in the lesional skin of APC
In normal skin corresponding to case 8 in Table 1, the
epidermis showed a weak reaction with the Ab for CD36, a
relatively positive reaction with the Ab for RAGE, and no
reaction with the anti-SR-A Ab (Figure 6, upper panel).
Staining intensity of normal skin with the Abs for both SR-BI
and Gal-3 was lower than that for RAGE (data not shown).
These immunohistochemical data are compatible with
previous reports (Be´ge´ny et al., 1994; Tsuruoka et al., 2002;
Lohwasser et al., 2006) in which RAGE and CD36 were
expressed weakly in the human epidermis. In the skin of the
patients, the anti-SR-A Ab did not react with the epidermis of
the lesional skin, whereas the anti-RAGE Ab reacted with the
epidermis of the lesional skin to the same extent as with the
epidermis of normal skin. Staining intensity of immunor-
eactivity of the lesional epidermis with anti-SR-BI and Gal-3
Abs was lower than that with anti-RAGE Ab (data not shown).
Compared with the staining intensity of normal skin, the Ab
for CD36 reacted strongly with the epidermis around the
collagenous materials being extruded (Figure 6, middle and
lower panels). In normal skin (case 8 in Table 1), the
epidermis showed very weak reaction with the anti-MMP-9
Ab (Figure 6, upper panel), as has previously been reported
(Kobayashi etal., 1996). Compared with the staining intensity
of normal skin, the Ab for MMP-9 reacted strongly, with the
epidermis around the collagenous materials being extended
(Figure 6, middle and lower panels). Neither normal nor
patient skin reacted with the Ab for MMP-2 (data not shown).
A summary of the immunohistochemical staining for seven
cases of APD and four healthy controls is presented in
Table 1. The staining intensity of CD36 and MMP-9 in the
seven cases of APD was found to be variable (weakly positive
to very strongly positive), possibly because of the difference
in the disease stage or the sliced site of the lesional skin
specimen.
DISCUSSION
To our knowledge, there has been no reported immunohis-
tological evidence that the epidermis extrudes denatured
collagen in APD that overexpresses CD36. The induction of
CD36 mRNA in KCs by AGE-modified collagen I or III
substrate, partial inhibition of glycated collagen-induced INV
expression by a neutralizing anti-CD36 Ab, and a coordinate
induction of INV and CD36 expression during terminal
differentiation strongly suggest that CD36 mediates glycated
collagen-induced terminal differentiation. Although binding
assays between CD36 of cultured KCs and AGE-modified
collagen I and III substrates were not conducted in this study,
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Figure 1. Expression of involucrin and keratin 10 in response to unmodified or advanced glycation end product (AGE)-modified extracellular matrix (ECM)
substrates in cultured keratinocytes. Keratinocytes were grown on unmodified or AGE-modified collagens (col) I, III, IV, and V; fibronectin (FN); or laminin (LN)
for 12, 24, and 48 hours. RNA was isolated from the cells, and real-time PCR was performed that was directed to the involucrin and keratin 10 mRNAs.
Values are expressed as the ratio of AGE-modified substrates (closed columns) relative to the unmodified substrates (open columns). Numbers are mean±SD
(n¼6). *Statistical significance at Po0.05.
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a direct interaction of CD36 with AGE has been shown by
binding experiments in which 125I-AGE-BSA showed specific
and saturable binding to CD36 expressed by CHO cells
(Kd¼5.6 mgml1) and by a blocking Ab assay in which anti-
CD36 Ab inhibited the cellular binding of oxidized low-
density lipoprotein with 125I-AGE-BSA by 60% (Ohgami
et al., 2001a). In the present study, using cultured KCs
and AGE-modified type I collagen substrate, neutralizing
anti-CD36 Ab showed a statistically significant but somewhat
lower inhibition (27.7 vs 60%). The lower inhibition is
possibly due to differences between cell species (CHO cells
overexpressing CD36 vs KCs) or the type of substrate (BSA
vs collagens) or the involvement of other, as yet unidenti-
fied AGE receptors. KC CD36, previously believed to be
involved only in scavenging activity, may have an important
role in the TEE of the dermal matrix. Overexpression of
epidermal CD36 has been reported in acute uninfla-
med wounds, in which suprabasal KCs positively expres-
sing CD36 were observed as early as 30minutes after
wounding in the adjacent epidermis but disappeared
shortly after 4 days (Simon et al., 1996). Overexpression
of CD36 in the epidermis of APD is unrelated to over-
expression in acute wounding because the skin lesions
(keratotic papules or nodules) in APD are chronic lesions
that persist for years.
Cultured KCs adhere and grow more efficiently on ECM
(collagens I, III, and IV; fibronectin; and laminin)-coated
dishes (Kubo et al., 1987; Woodley et al., 1990) than on
uncoated dishes. The interaction of KCs with ECM is
generally mediated by a variety of integrins that promote
the progression through the G1 phase of the cell cycle
(Giancotti and Ruoslahti, 1999). Integrin a2b1 is known to
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Figure 2. Expression of advanced glycation end product (AGE) receptors in response to AGE-modified collagens (col) I and III or fibronectin (FN) substrates
in cultured keratinocytes. Keratinocytes were cultured on unmodified or AGE-modified collagens I and III or on FN substrate for 12, 24, and 48 hours.
Relative mRNA levels of CD36, galectin-3 (Gal-3), receptor for advanced glycation end product (RAGE), and class B scavenger receptor type I (SR-BI) were
determined and presented as described in Figure 1. Numbers are mean±SD (n¼ 6). *Statistical significance at Po0.05.
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have a major role in the migration and adhesion of KCs on
collagen I (Knight et al., 1998). It was observed that glycated
collagens I and III induced KC differentiation, but glycated
collagens IV and V, fibronectin, and laminin did not. Because
a glycated collagen I substrate has been reported to diminish
KC adhesion by a mechanism unrelated to altered integrin
expression or function (Morita et al., 2005; our unpublished
experiment), AGE-modified collagen species-specific effects
on KCs may be, at least partially, dependent on the
supramolecular structure of the AGE-modified collagen
species.
Glycated collagen I and III substrate-enhanced MMP-9
expression and its proteolytic activity in cultured KCs are
associated with the degradation of basement membrane
components, including type IV, V, and VII collagens
(Birkedal-Hansen, 1995), which allows the interaction
between KCs and dermal ECM (mainly collagens I and III).
Once the interaction of KCs with AGE-modified collagen I
or III is induced by minor trauma or scratching, further
degradation of the dermal–epidermal junction will occur
via enhanced MMP-9 expression. This cycle may be
self-enhancing and thereby promote the progression of the
TEE of collagen (Figure 7).
Although these results are still preliminary and insufficient,
we attempted to hypothesize the process of TEE as follows
(Figure 7). First, in the initial phase, minor trauma or
scratching due to severe pruritus in patients with diabetes
mellitus or chronic renal failure who require hemodialysis
causes dermal–epidermal junction damage, allowing the KCs
to be exposed to AGE-modified dermal interstitial collagens.
Second, during wound repair, KCs migrate to the dermal ECM
and interact with AGE-modified collagen I or III (major
collagens in the dermis) through the AGE receptor (CD36).
Finally, KCs terminally differentiate and migrate with KC-
bound modified collagens upward from the basal to the horny
layers. Enhanced MMP-9 expression induced by glycated
collagen I or III may contribute to further degradation of the
dermal–epidermal junction.
Transepidermal elimination will be very complex and
comprise multi-step processes. To establish in vitro experi-
ments representing the total process of TEE in vivo will
therefore be very difficult and does not yet seem feasible.
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In the study described here, we focused on the epidermal–-
dermal interaction that occurs in TEE using the KC culture
system. Our hypothesis on the interaction is the first step in
understanding the molecular mechanism of TEE.
MATERIALS AND METHODS
Preparation of glycated ECM proteins
Six- and 96-well plates coated with collagen (I, III, and IV),
fibronectin, and laminin were purchased from BD BioCoat Cellware
(Bedford, MA). To modify the ECM components of the cultured
dishes, 0.2 M D-ribose (SERVA, Heidelberg, Germany) in a 0.2 M
phosphate-buffered solution (pH 7.4) was added to each well under
sterile conditions, and the dishes were maintained at 37 1C for 2
weeks. Excess ribose was removed by washing several times with
sterile phosphate-buffered saline. A noncompetitive ELISA was per-
formed to detect AGE in ECM proteins. The wells were blocked with
100ml of 1% BSA in washing buffer (0.05% Tween 20 in phosphate-
buffered saline) at room temperature for 1 hour and incubated with
100ml of anti-CML Ab (6D12) (1 mgml1) at room temperature for
2 hours. After three washes with washing buffer, the wells were
incubated with horseradish peroxidase-conjugated anti-mouse IgG
Ab at room temperature for 1 hour. The antigen–Ab complex was
visualized by 1,2-phenylenediamine dehydrochloride, and the
absorbance at 492nm was read with a plate reader (Morita et al., 2005).
Cell culture
Normal human KCs were purchased from Sanko-Junyaku (Tokyo,
Japan) and cultured in serum-free, low-calcium (0.1mM), modified
MCDB153 KC basal medium containing growth factors, insulin,
epidermal growth factor, hydrocortisone, and bovine pituitary
extract (KGM), and the third or fourth normal human KC cultures
were used in this experiment. KCs were grown on ECM-coated or
AGE-modified ECM-coated dishes at a density of 2.5 105 cells per
well for 12, 24, and 48 hours in KGM medium. To induce terminal
differentiation, KCs were trypsinized and suspended at a concentra-
tion of 2 105 cells per ml in KGM supplemented with 1.5%
methylcellulose (4,000 centipoises, Sigma-Aldrich, St Louis, MO)
and then incubated at 37 1C for 24 or 48 hours (Adams and Watt,
1989).
Total RNA isolation, cDNA synthesis, and reverse
transcriptase–PCR
Total RNA was isolated from cultured KCs using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). The extracted RNA was dissolved in
diethylpyrocarbonate-treated water and quantified spectrophotome-
trically at a wavelength of 260 nm. cDNA was produced by the
reverse transcription reaction (cDNA synthesis kit, Fermentas, Burlington,
ON, Canada) and stored at 80 1C for subsequent analyses. Reverse
transcriptase–PCR was performed using a 7900 HT Real-Time PCR
system (Applied Biosystems, Foster City, CA) according to the
supplier’s recommendations. Primers and probes (TaqMan Assays-
on-Demand Gene Expression Products) of the genes for human
CD36, RAGE, Gal-3, SR-BI, MMP-2, MMP-9, K10, INV, integrin b1,
integrin a2, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were designed by Applied Biosystems from gene sequences
obtained from GenBank (accession nos.: NM001001548.1 for CD36,
NM172197.1 for RAGE, NM002306.2 for Gal-3, NM001082959.1
for SR-BI, NM004530.2 for MMP-2, NM004994.2 for MMP-9,
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collagens I, III, and IV and fibronectin (FN) substrates. (a) Keratinocytes were cultured on unmodified and AGE-modified collagens (col) (I, III, and IV) and
FN for 12, 24, and 48 hours. RNA was isolated, and the MMP-2 and MMP-9 mRNA levels were determined by real-time PCR. (b) Keratinocytes were cultured
on unmodified and AGE-modified collagen I for 12, 24, and 48 hours. Cultured media were recovered from the cells. Proteins were precipitated with 10%
trichloroacetic acid. MMP-2 and MMP-9 levels were measured with one-step sandwich enzyme-linked immunoassay using an mAb kit (left and middle).
The proteins were resolved on 7.5% SDS-PAGE containing 0.5% gelatin. Gelatin zymography was performed at 35 1C for 3 hours (right).
Table 1. Immunohistochemical studies of lesional skin in the patients with acquired perforating dermatosis
Immunoreactivity of epidermis with
Age/sex Site Clinical features RAGE CD36 Gal-3 SR-BI SR-A MMP-2 MMP-9
1 79/F Thigh DM for 30 years, dialysis for 9 years + ++ ± ±   ++
2 71/M Back DM for 10 years + +++     ++
3 59/M Lumbus DM for 24 years, dialysis for 4 years + ++ ±    +
4 68/M Buttock DM for 12 years, dialysis for 4 years + ++ ±    +
5 70/F Thigh DM for 35 years, dialysis for 10 years + +++  ±   ++
6 67/M Thigh DM for 37 years, dialysis for 8 years + ++     ±
7 40/M Lumbus DM for 10 years, dialysis for 3 years + +     ±
8 44/M Back Normal + ± ± ±   ±
9 70/M Thigh Normal +  ±    
10 36/M Lumbus Normal +      ±
11 47/M Back Normal +      
+++, very strong positive; ++, strongly positive; +, positive; ±, slightly positive; , negative, DM, diabetes mellitus; F, female; Gal-3, galectin-3; M, male;
MMP, matrix metalloproteinase; RAGE, receptor for advanced glycation end product; SR-A, macrophage class A scavenger receptor; SR-BI, class B
scavenger receptor type I.
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NM000421.2 for K10, NM005547.2 for INV, NM033667.2 for integrin
b1, NM002203.3 for integrin a2, and NM002046.3 for GAPDH). The
relative mRNA amounts of the selected genes were calculated using
the standard curve method. The quantity of mRNA was normalized to
the quantity of GAPDH mRNA in each cDNA sample.
Neutralizing Abs
Commercially available neutralizing Abs for CD36 (FA6-152) and
RAGE (176902) were obtained from Abcam (Cambridge, UK) and
R&D Systems (Minneapolis, MN), respectively, and used as
previously described (Dawson et al., 1997; Oldfield et al., 2001;
Ohgami et al., 2001a).
Double immunofluorescence technique
Cells that were suspended in 1.5% methylcellulose for 0 or 48 hours
were placed on a slide glass, fixed with acetone, and incubated with
monoclonal anti-human CD36 (Ancell, Bayport, MN) or polyclonal
anti-human INV Ab (Abcam). Bound Ab was visualized using
fluorescence-conjugated secondary Abs.
ELISA for MMP-2 and MMP-9, and gelatin zymography
MMP-2 and MMP-9 levels were measured with one-step sandwich
ELISA using an mAb kit (Daiichi Fine Chemical, Toyama, Japan)
according to the manufacturer’s instructions. Briefly, the culture
medium was mixed with anti-MMP-2 and MMP-9 IgG–horseradish
peroxide conjugate. The mixture was incubated with bead-con-
jugated anti-MMP-2 and MMP-9 Abs for 2 hours at room tempera-
ture and then washed three times with 0.01M phosphate-buffered
saline. The assay for horseradish peroxidase activity bound on the
beads was started by adding 0.15M citric acid sodium phosphate
buffer containing 2.0 g l1 o-phenylenediamine and 0.02% hydrogen
peroxide and incubated for 30minutes at room temperature. The
reaction was stopped by the addition of sulfuric acid, and the
absorbance at 492 nm was measured by a microplate reader.
Zymography was performed as reported previously (Kobayashi,
2005). Briefly, proteins from the conditioned medium were
precipitated with 10% trichloroacetic acid, dissolved in sample
CD36
Normal
skin
Patient 1
Patient 2
SR-A RAGE MMP-9
Figure 6. Immunostaining of the lesional skin obtained from patients with acquired perforating dermatosis using antibodies for the advanced glycation
end product (AGE) receptors (CD36, SR-A, and RAGE) and matrix metalloproteinase 9 (MMP-9). Normal skin corresponding to case 8 in Table 1 (upper
panel) and lesional skin of patients corresponding to cases 1 and 2 in Table 1 (middle and lower panels) were fixed with paraffin, sliced at 5-mm thickness,
and incubated with antibodies (1:200) for CD36, macrophage class A scavenger receptor (SR-A), receptor for advanced glycation end product (RAGE),
and MMP-9 overnight at 4 1C. The sections were incubated with anti-mouse, -rabbit, or -goat Ig antibody at 1:600 for 1 hour. The antigen–antibody complex
was visualized by the avidin–biotin complex. Bars¼ 200mm. D, dermis; E, epidermis; M, extruded material.
Scratch 1st stage
2nd stage
3rd stage
BMZ damage
MMP-9
Upward migration of KC together with
AGE-modified collagen
Induction of terminal differentiation
TEE
Interaction of KC with AGE-modified
collagen via AGE receptor
Exposure of KCs to AGE-modified type
I, III collagen
Figure 7. Summary of the molecular mechanism of transepidermal
elimination (TEE). Hypothesis of the development of TEE of advanced
glycation end product (AGE)-modified collagen in patients with acquired
perforating dermatosis associated with diabetes mellitus and renal
insufficiency. BMZ, basement membrane zone.
412 Journal of Investigative Dermatology (2010), Volume 130
E Fujimoto et al.
Interaction of Keratinocytes with Glycated Collagen
buffer (0.05M Tris-HCl, pH 7.4, 5mM CaCl2, 1% SDS, 0.02%
bromophenol blue, and 30% glycerol) without reduction or boiling,
and separated by 7.5% SDS-PAGE containing 0.5% gelatin. Cells
were counted after trypsin treatment. The amount of proteins applied
to gels was adjusted to the cell number. After electrophoresis,
the gels were washed with 2.5% Triton X-100 for 1 hour to remove
the SDS. Gelatinolytic zymography reactions were induced by
incubating the gels in the reaction buffer (0.05M Tris-HCl, pH 7.4,
0.15M NaCl, 5mM CaCl2, and 0.02% NaN3) at 35 1C for 3 hours.
Gels were stained with 0.1% amido black B-10 and destained with
10% acetic acid/30% methanol.
Skin specimens
A biopsy of the lesional skin of APD patients was performed. The
patients were diagnosed on the basis of histological and clinical
features. Normal control skin was obtained from a normal-appearing
area of a benign skin tumor, such as a nevus, an epidermal cyst, or
seborrheic keratosis.
Immunohistochemistry
Monoclonal anti-human CD36 (Ancell), polyclonal anti-human
scavenger SR-BI (Novus Biologicals, Littleton, CO), polyclonal
anti-human RAGE (Chemicon International, Temecula, CA), poly-
clonal anti-human Gal-3 (Cosmo Bio, Tokyo, Japan), polyclonal
anti-human SR-A (Santa Cruz Biotechnology, Santa Cruz, CA), and
monoclonal anti-human MMP-2 and MMP-9 (Cosmo Bio) Abs were
used for the immunohistochemical studies. Abs for each antigen
were diluted 1:200, blocked with 1% BSA, and applied and left
overnight at 4 1C. The slides were washed with Tris-buffered saline
for 30minutes and then incubated with biotin-conjugated secondary
anti-mouse, -rabbit, or -goat immunoglobulin Ab for 60minutes at a
dilution of 1:600. The antigen–Ab complex was visualized using the
avidin–biotin complex.
This study was approved by the Ethics Committee Board of the
National Defense Medical College, Japan. The study was conducted
according to the Declaration of Helsinki Principles, and patients
gave their written informed consent.
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